Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL.
DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies
Diffuse Large B-Cell Lymphoma Emerging Drugs Profile
Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.
RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
The Diffuse Large B-Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.
Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs
Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
10 hours ago
- CTV News
China's exports jump 5.8% in June as tariffs reprieve prompts a rush of orders
BANGKOK — China's exports accelerated in June as a reprieve on U.S. tariffs prompted a rush of orders by companies and consumers ahead of an August deadline. Exports climbed 5.8 per cent from a year earlier, up from a 4.8 per cent rise in May. Imports also recovered, growing 1.1 per cent in the first increase so far this year, according to customs data released Monday. Exports to the United States fell 16 per cent, but that was less than half the 34.5 per cent drop seen in May. After U.S. President Donald Trump imposed tariffs of up to 245 per cent on imports from China and Beijing responded with its own steep import duties, the two sides agreed to a truce to allow time for talks. The retailers and other importers that had largely halted shipments of shoes, clothes, toys, and other items due to new tariffs then resumed imports from China. But preliminary discussions between the two sides have yet to produce significant progress and sudden changes in policy have raised uncertainty for companies trying to plan ahead. In the meantime, the Trump administration has hiked tariffs on imports from China by 30 per cent, pending an Aug. 12 deadline for reverting to the higher tariffs Washington and Beijing have delayed for now. The recovery in trade is expected to help boost economic growth in the April to June quarter. The Chinese government is due to report those figures on Tuesday. Still, the outlook is less upbeat, noted Zichun Huang of Capital Economics, noting that 'tariffs are likely to remain high and Chinese manufacturers face growing constraints on their ability to rapidly expand global market share by slashing prices. 'We therefore expect export growth to slow over the coming quarters, weighing on economic growth,' Huang said in a report. Data for the first six months of the year showed that while the trade war with the U.S. heated up following Trump's return to the White House, China's global trade kept growing. Total trade including exports and imports hit a record of more than 20 trillion yuan (US$2.8 trillion) as Chinese businesses diversified their overseas production and export markets. China's global trade surplus in the first half of the year hit $586 billion. Exports to Southeast Asia grew 13 per cent year-on-year in January to June, with shipments to Thailand up 22 per cent, to Vietnam up nearly 20% and to India up more than 18 per cent. Trade with Europe also was brisk, climbing 6.6 per cent in the first half of the year from a year earlier. But auto exports fell after the European Union imposed higher tariffs on Chinese-made electric vehicles, sinking nearly 38 per cent from a year earlier. Exports of auto parts fell more than 23 per cent. Elaine Kurtenbach, The Associated Press
CTV News
10 hours ago
- CTV News
World shares are mixed as investors focus on tariffs and earnings
A person stands in front of an electronic stock board showing Japan's Nikkei index at a securities firm in Tokyo. (AP Photo/Eugene Hoshiko) BANGKOK — World shares were mixed on Monday as investors focused on tariffs and corporate earnings updates. An announcement over the weekend by U.S. President Donald Trump that he plans 30 per cent tariffs on goods from Mexico and the European Union had a modest immediate impact, as analysts said they expected progress toward trade deals before an Aug. 1 deadline. Trump detailed the planned tariffs Saturday in letters posted to his social media account. The Mexican peso weakened slightly against the dollar, trading at 18.6 pesos to the dollar. Chinese shares advanced after the government reported that exports rose last month as a truce in a tariffs war prompted a surge in orders ahead of an Aug. 12 deadline for reaching a new trade deal with Washington. Hong Kong's Hang Seng gained 0.3% to 24,091.45, while the Shanghai Composite index also was up 0.3%, at 3,519.65. Tokyo's Nikkei 225 index slipped 0.3% to 39,459.62, while the Kospi in South Korea jumped 0.8% to 3,202.03. In Australia, the S&P/ASX 200 edged 0.1 per cent lower to 8,570.40. Taiwan's benchmark lost 0.6 per cent. On Friday, a modest pullback for U.S. stocks left major stock indexes on Wall Street in the red for the week. The S&P 500 closed 0.3 per cent lower, at 6,259.75, a day after setting a record high. The Dow Jones Industrial Average dropped 0.6 per cent to 44,371.51, and the Nasdaq composite gave up 0.2% to 20,585.53 after drifting between small gains and losses much of the day. The tech-heavy index was coming off its own all-time high on Thursday. The selling capped an uneven week in the market as Wall Street kept an eye on the Trump administration's rollout of new tariff threats against trading partners like Canada and looked ahead to the upcoming corporate earnings reporting season. Trump said in a letter Thursday that he will raise taxes on many imported goods from Canada to 35 per cent, deepening the rift between the longtime North American allies. The letter to Canadian Prime Minister Mark Carney was an aggressive increase to the top 25 per cent tariff rates that Trump first imposed in March. The administration had initially set Wednesday as a deadline for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, one with the United Kingdom and one with Vietnam, the window for negotiations has been been extended to Aug. 1. Trump also floated this week that he would impose tariffs of as much as 200% on pharmaceutical drugs and place a 50 per cent tariff on copper imports, matching the rates charged on steel and aluminum. The initial rollout of Trump's tariff policies in the spring roiled financial markets. But they have been relatively stable in recent weeks, suggesting investors have adjusted to the unpredictability of his sudden policy shifts. Markets are set to shift their focus to quarterly earnings over the next few weeks. JPMorgan Chase, Wells Fargo and Citigroup are among big banks due to report their results on Tuesday. Shares in aviation company Red Cat Holdings jumped 26.4 per cent Friday after Defense Secretary Pete Hegseth issued orders aimed at ramping up production and deployment of drones. Bitcoin climbed to another all-time high, rising 3.6 per cent early Monday to $121,914, according to CoinDesk. Bitcoin's price has jumped amid bullish momentum across risk assets and coincides with Nvidia's surge to a US$4 trillion valuation. The U.S. Congress' Crypto Week starts Monday. Lawmakers will debate a series of bills that could define the regulatory framework for the industry. In other dealings early Monday, U.S. benchmark crude oil gained 45 cents to $68.90 per barrel. Brent crude, the international standard, was up 44 cents at $70.80 per barrel. The dollar slipped to 147.22 Japanese yen from 147.38 yen. The euro fell to $1.1685 from $1.1692. Elaine Kurtenbach, The Associated Press
Globe and Mail
11 hours ago
- Globe and Mail
World shares are mixed as investors focus on tariffs and earnings
BANGKOK (AP) — World shares were mixed on Monday as investors focused on tariffs and corporate earnings updates. An announcement over the weekend by U.S. President Donald Trump that he plans 30% tariffs on goods from Mexico and the European Union had a modest immediate impact, as analysts said they expected progress toward trade deals before an Aug. 1 deadline. Trump detailed the planned tariffs Saturday in letters posted to his social media account. The Mexican peso weakened slightly against the dollar, trading at 18.6 pesos to the dollar. Chinese shares advanced after the government reported that exports rose last month as a truce in a tariffs war prompted a surge in orders ahead of an Aug. 12 deadline for reaching a new trade deal with Washington. Hong Kong's Hang Seng gained 0.3% to 24,091.45, while the Shanghai Composite index also was up 0.3%, at 3,519.65. Tokyo's Nikkei 225 index slipped 0.3% to 39,459.62, while the Kospi in South Korea jumped 0.8% to 3,202.03. In Australia, the S&P/ASX 200 edged 0.1% lower to 8,570.40. Taiwan's benchmark lost 0.6%. On Friday, a modest pullback for U.S. stocks left major stock indexes on Wall Street in the red for the week. The S&P 500 closed 0.3% lower, at 6,259.75, a day after setting a record high. The Dow Jones Industrial Average dropped 0.6% to 44,371.51, and the Nasdaq composite gave up 0.2% to 20,585.53 after drifting between small gains and losses much of the day. The tech-heavy index was coming off its own all-time high on Thursday. The selling capped an uneven week in the market as Wall Street kept an eye on the Trump administration's rollout of new tariff threats against trading partners like Canada and looked ahead to the upcoming corporate earnings reporting season. Trump said in a letter Thursday that he will raise taxes on many imported goods from Canada to 35%, deepening the rift between the longtime North American allies. The letter to Canadian Prime Minister Mark Carney was an aggressive increase to the top 25% tariff rates that Trump first imposed in March. The administration had initially set Wednesday as a deadline for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, one with the United Kingdom and one with Vietnam, the window for negotiations has been been extended to Aug. 1. Trump also floated this week that he would impose tariffs of as much as 200% on pharmaceutical drugs and place a 50% tariff on copper imports, matching the rates charged on steel and aluminum. The initial rollout of Trump's tariff policies in the spring roiled financial markets. But they have been relatively stable in recent weeks, suggesting investors have adjusted to the unpredictability of his sudden policy shifts. Markets are set to shift their focus to quarterly earnings over the next few weeks. JPMorgan Chase, Wells Fargo and Citigroup are among big banks due to report their results on Tuesday. Shares in aviation company Red Cat Holdings jumped 26.4% Friday after Defense Secretary Pete Hegseth issued orders aimed at ramping up production and deployment of drones. Bitcoin climbed to another all-time high, rising 3.6% early Monday to $121,914, according to CoinDesk. Bitcoin's price has jumped amid bullish momentum across risk assets and coincides with Nvidia's surge to a $4 trillion valuation. The U.S. Congress' Crypto Week starts Monday. Lawmakers will debate a series of bills that could define the regulatory framework for the industry. In other dealings early Monday, U.S. benchmark crude oil gained 45 cents to $68.90 per barrel. Brent crude, the international standard, was up 44 cents at $70.80 per barrel. The dollar slipped to 147.22 Japanese yen from 147.38 yen. The euro fell to $1.1685 from $1.1692.
